Monoclonal Antibodies in Multiple Sclerosis: Present and Future
The global incidence of multiple sclerosis (MS) appears to be increasing. Although it may not be associated with a high mortality rate, this disease has a high morbidity rate which affects the quality of life of patients and reduces their ability to do their activities of daily living. Thankfully, t...
Main Authors: | Natalia V. Voge, Enrique Alvarez |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-03-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | http://www.mdpi.com/2227-9059/7/1/20 |
Similar Items
-
by: Jagannadha Avasarala
Published: (2017-11-01) -
Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review
by: Elsbernd PM, et al.
Published: (2021-06-01) -
Multiple Sclerosis Diagnosis and Treatment
Published: (2022) -
Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review
by: Katja Schmitz, et al.
Published: (2017-09-01) -
Production and Characterization of New Anti-Human CD20 Monoclonal Antibody
by: Mahdi Fasihi-Ramandi, et al.
Published: (2015-10-01)